The EBMT risk score

Bone Marrow Transplantation

Volumn 47, Issue 6, 2012, Pages 749-756

  Gratwohl, A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

allogeneic; autologous; EBMT risk score; hematopoietic SCT; risk assessment

Indexed keywords

AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DISEASE STAGE; DONOR RECIPIENT GENDER COMBINATION; DONOR TYPE; EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION RISK SCORE; HEMATOLOGIC MALIGNANCY; HUMAN; MEDICAL DECISION MAKING; MORTALITY; NON RELAPSE MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; TIME INTERVAL FROM DIAGNOSIS TO TRANSPLANT;

AGE FACTORS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LIVING DONORS; MALE; RISK ADJUSTMENT; SEX FACTORS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84862188963     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.110     Document Type: Review

References (43)

1. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087-1092.
2. Gratwohl A, Passweg J, Baldomero H, Hermans J, Urbano-Ispizua A. Hematopoietic stem cell transplantation in Europe 1998. Hematol J 2000; 1: 333-350.
3. Armitage JO. Bone marrow transplantation. N. Engl. J. Med. 1994; 330: 827-838.
4. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation. N. Engl. J. Med. 1975; 292: 895-902.
5. Sierra J, Storer B, Hansen JA, Bjerke JW, Martin PJ, Petersdorf EW et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997; 89: 4226-4235.
6. Goulmy E, Termijtelen A, Bradley BA, Van Rood JJ. Alloimmunity to human H-Y. Lancet 1976; 2: 1206.
7. European Group for Bone Marrow Transplantation. Allogeneic bone marrow transplantation for leukaemia in Europe. Report from the Working Party on Leukaemia. Lancet 1988; 1: 1379-1382.
8. Gratwohl A. Biological differences in the three major leukaemias. Lancet 1988; 2: 403.
9. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology. Blood 1999; 94: 1517-1536.
10. Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004; 125: 613-620.
11. De Souza CA, Vigorito AC, Ruiz MA, Nucci M, Dulley FL, Funcke V et al. Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome. Haematologica 2005; 90: 232-237.
12. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513-521.
13. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: An analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969-2976.
14. Craddock C, Szydlo RM, Dazzi F, Olavarria E, Cwynarski K, Yong A et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: The case for tailored graft-versus-host disease prophylaxis. Br J Haematol 2001; 112: 228-236.
15. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: Evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115: 1880-1885.
16. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N. Engl. J. Med. 1998; 339: 1649-1656.
17. Gahrton G. Risk assessment in haematopoietic stem cell transplantation: Impact of donor-recipient sex combination in allogeneic transplantation. Best Pract Res Clin Haematol 2007; 20: 219-229.
18. Van Besien K. Allogeneic stem cell transplantation in follicular lymphoma: Recent progress and controversy. Hematology Am Soc Hematol Educ Program 2009, 610-618.
19. Kröger N, Brand R, Van Biezen A, Zander A, Dierlamm J, Niederwieser D et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 2009; 94: 542-549.
20. Gupta V, Eapen M, Brazauskas R, Carreras J, Aljurf M, Gale RP et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica 2010; 95: 2119-2125.
21. Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, De Witte T et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: A retrospective analysis. Cancer 2009; 115: 4715-4726.
22. Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J et al. Introduction of a quality management system and outcome after hematopoietic stem cell transplantation. J Clin Oncol 2010 (e-pub ahead of print 11 April 2011).
23. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N. Engl. J. Med. 1999; 341: 1051-1062.
24. Zwaan FE, Hermans J, Barrett AJ, Speck B. Bone marrow transplantation for acute nonlymphoblastic leukaemia: A survey of the European Group for Bone Marrow Transplantation (EBMT). Br J Haematol 1984; 56: 645-653.
25. Shaw BE, Arguello R, Garcia-Sepulveda CA, Madrigal JA. The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation. Br J Haematol 2010; 150: 251-258.
26. Petersdorf EW. Optimal HLA matching in hematopoietic cell transplantation. Curr Opin Immunol 2008; 20: 588-593.
27. Chalandon Y, Tiercy JM, Schanz U, Gungor T, Seger R, Halter J et al. Impact of high-resolution matching in allogeneic unrelated donor stem cell transplantation in Switzerland. BMT 2006; 37: 909-916.
28. Schlenk RF, Döhner K, Mack S, Stoppel M, Király F, Götze K et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 2010; 28: 4642-4648.
29. Stern M, Brand R, De Witte T, Sureda A, Rocha V, Passweg J et al. Female-versus-male alloreactivity as a model for minor histocompatibility antigens in hematopoietic stem cell transplantation. Am J Transplant 2008; 8: 2149-2157.
30. Spierings E, Vermeulen CJ, Vogt MH, Doerner LE, Falkenburg JH, Mutis T et al. Identification of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation. Lancet 2003; 362: 610-615.
31. Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105: 2973-2978.
32. Gratwohl A, Döhler B, Stern M, Opelz G. H-Y as a minor histocompatibility antigen in kidney transplantation: A retrospective cohort study. Lancet 2008; 372: 49-53.
33. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 2010; 24: 319-337.
34. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28: 3730-3738.
35. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-4583.
36. Crocchiolo R, Ciceri F, Fleischhauer K, Oneto R, Bruno B, Pollichieni S et al. HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: A study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. Bone Marrow Transplant 2009; 44: 571-577.
37. Rowe JM. Optimal induction and post-remission therapy for AML in first remission. Hematology Am Soc Hematol Educ Program 2009, 396-405.
38. Lodewyck T, Cornelissen JJ. Allogeneic stem cell transplantation in acute myeloid leukemia: A risk-Adapted approach. Blood Rev 2008; 22: 293-302.
39. Gratwohl A. Risk assessment in haematopoietic stem cell transplantation. Best Pract Res Clin Haematol 2007; 20: 119-124.
40. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 2010; 363: 2091-2101.
41. Passweg J, Baldomero H, Stern M, Bargetzi M, Ghielmini M, Leibundgut K et al. Hematopoietic stem cell transplantation in Switzerland: A comprehensive quality control report on centre effect. Swiss Med Wkly 2010; 140: 326-334.
42. Lin MY, Hota B, Khan YM, Woeltje KF, Borlawsky TB, Doherty JA et al. Quality of traditional surveillance for public reporting of nosocomial bloodstream infection rates. JAMA 2010; 304: 2035-2041.
43. Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simon JA et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010; 28: 4521-4530.